Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciaf597 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Charlotte Rolle und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Operations, Orlando Immunology Center, Orlando, Florida, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Drug Resistance, Multiple, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Theratechnologies Inc.
Abstract (Originalsprache)
Background
Some individuals with human immunodeficiency virus (HIV-1) have acquired multidrug-resistant (MDR) strains of HIV and/or are nonadherent to antiretroviral (ARV) medication. Injectable ARVs can provide salvage therapy for those with limited therapeutic options and may be preferred by some people with HIV (PWH). Real-world evidence may contribute to a more comprehensive understanding of the barriers to adherence and the utility of injectable ARVs in PWH. Currently, there is a lack of data on combined use of injectable ibalizumab (IBA) and lenacapavir (LEN) with optimized background regimen (OBR).
Methods
A retrospective observational study examined medical charts from people with MDR HIV across 8 facilities in the United States. All PWH used a combination of both IBA + LEN ± OBR for at least 6 months. Viral loads and CD4+ counts were collected.
Results
A total of 21 PWH were included. Four-class resistance at baseline was reported in 38.1% of PWH. Within 12 to 24 weeks of combined IBA + LEN treatment, a median reduction of −2710 copies/mL HIV RNA was observed. Median increase to CD4+ count was 67.5 cells/mm3 within 4 to 44 weeks of treatment initiation. Few intolerances required changes to treatment. Therapy with IBA + LEN continued for an average of 30 months and 20 months, respectively.
Conclusions
In this small group of individuals with MDR HIV who were heavily treatment-experienced and/or faced adherence challenges, the use of IBA + LEN ± OBR was well tolerated and led to clinically significant reductions in viral loads and improvements in CD4+ counts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Operations, Orlando Immunology Center, Orlando, Florida, USA.
- Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
- Clinical Pharmacy, Prism Health North Texas, Dallas, Texas, USA.
- Rutgers Health, New Jersey Medical School, Newark, New Jersey, USA.
- Shore Medical Center, South Jersey Infectious Disease, Somers Point, New Jersey, USA.
- Clinical/Medical and Research Divisions, The Research Institute, Springfield, Massachusetts, USA.
ORCID-Profile: Amit Achhra, Jihad Slim
Förderung
- Theratechnologies Inc
Zitieren
APA
Rolle, C., Achhra, A., Harbison, C., Finkel, D., Lucasti, C., Martorell, C., McClendon, T., & Slim, J. (2026). Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf597
Vancouver
Rolle C, Achhra A, Harbison C, Finkel D, Lucasti C, Martorell C, et al. Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf597
BibTeX
@article{Rolle2026,
author = {Rolle, Charlotte and Achhra, Amit and Harbison, Christina and Finkel, Diana and Lucasti, Christopher and Martorell, Claudia and McClendon, Tammie and Slim, Jihad},
title = {Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciaf597}
}
EUVIMED